How does DOA's PS Ratio compare to its peers?

DOA is good value based on its Price-To-Sales Ratio (9.1x) compared to the peer average (16.1x).

How does DOA's PS Ratio compare vs other companies in the DE Biotechs Industry?

DOA is expensive based on its Price-To-Sales Ratio (9.1x) compared to the European Biotechs industry average (8.1x).

What is DOA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DOA is good value based on its Price-To-Sales Ratio (9.1x) compared to the estimated Fair Price-To-Sales Ratio (12.9x).

What is the Fair Price of DOA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate DOA's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Soligenix (DB:DOA) - Stock Price, News & Analysis

DOA Stock Overview

A late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. More details

DOA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Revenue is forecast to grow 75.85% per year

Risk Analysis

Earnings are forecast to decline by an average of 1.5% per year for the next 3 years

Does not have a meaningful market cap (€9M)

Makes less than USD$1m in revenue ($949K)

Negative shareholders equity

+ 3 more risks

Soligenix, Inc. Competitors

Medigene

XTRA:MDG1

€20.6m

co.don

XTRA:CNW

€6.5m

Epigenomics

DB:ECX

€1.1m

Bellicum Pharmaceuticals

BST:BPXA

€772.4k

Price History & Performance

Summary of all time highs, changes and price drops for Soligenix
Historical stock prices
Current Share Price	US$5.85
52 Week High	US$14.11
52 Week Low	US$5.58
Beta	1.74
11 Month Change	0%
3 Month Change	-5.11%
1 Year Change	-10.53%
33 Year Change	-73.29%
5 Year Change	-71.94%
Change since IPO	-77.87%

Recent updates

Shareholder Returns

	DOA	DE Biotechs	DE Market
7D	0%	0.8%	0.8%
1Y	-10.5%	-18.3%	8.6%

Return vs Industry: DOA exceeded the German Biotechs industry which returned -23.1% over the past year.

Return vs Market: DOA underperformed the German Market which returned 5.9% over the past year.

Price Volatility

Is DOA's price volatile compared to industry and market?
DOA volatility
DOA Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: DOA has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine DOA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1987	14	Christopher Schaber	www.soligenix.com

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer.

Soligenix, Inc. Fundamentals Summary

How do Soligenix's earnings and revenue compare to its market cap?
DOA fundamental statistics
Market cap	€7.89m
Earnings (TTM)	-€12.59m
Revenue (TTM)	€865.50k

9.1x

P/S Ratio

-0.6x

P/E Ratio

Is DOA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DOA income statement (TTM)
Revenue	US$948.91k
Cost of Revenue	US$550.82k
Gross Profit	US$398.09k
Other Expenses	US$14.20m
Earnings	-US$13.80m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-1.45
Gross Margin	41.95%
Net Profit Margin	-1,454.12%
Debt/Equity Ratio	-400.6%

How did DOA perform over the long term?

See historical performance and comparison

DOA Stock Overview

Rewards

Risk Analysis

Soligenix, Inc. Competitors

XTRA:MDG1

€20.6m

XTRA:CNW

€6.5m

DB:ECX

€1.1m

BST:BPXA

€772.4k

Price History & Performance

Recent News & Updates

Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Initiates A Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behcet's Disease

Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference

Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Recent updates

Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Initiates A Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behcet's Disease

Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference

Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa

Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease

Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq

Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors

Soligenix, Inc. Receives Refusal to File Letter from U.S. FDA for Hybryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Publication Demonstrating Positive Correlates of Protection with Rivax® in Non-Human Primate Survival After Ricin Challenge

Soligenix, Inc. Initiates Phase 2 Clinical Trial of SGX302 (Synthetic Hypericin) for the Treatment of Mild-To-Moderate Psoriasis

Soligenix Announces Submission of New Drug Application to the FDA for Hybryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Receives Non Compliance Notice from Nasdaq

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$0.088 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$0.088 loss in 3Q 2021)

Soligenix, Inc. Announces U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Second quarter 2022 earnings released: US$0.055 loss per share (vs US$0.047 loss in 2Q 2021)

Soligenix, Inc., Annual General Meeting, Sep 22, 2022

Soligenix, Inc. Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in Treatment of Psoriasis

Soligenix Announces Successful Protection Using A Bivalent Thermostabilized Filovirus Vaccine

Soligenix Receives US Patent Allowance for Its Thermostabilized Vaccine Platform

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.064 loss in 1Q 2021)

Insufficient new directors

No longer forecast to breakeven

Full year 2021 earnings released: US$0.31 loss per share (vs US$0.64 loss in FY 2020)

Soligenix, Inc. Demonstrates Positive Anti-Tumor Efficacy in Multiple Nonclinical Animal Studies

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.088 loss per share (vs US$0.061 loss in 3Q 2020)

Insufficient new directors

Shareholder Returns

Price Volatility

About the Company

Soligenix, Inc. Fundamentals Summary

9.1x

-0.6x

Earnings & Revenue